A Regina mother who was one of the first ALS patients to test a new treatment is now celebrating its accelerated approval in ...

Denali Therapeutics’ amyotrophic lateral sclerosis (ALS) drug has racked up another clinical miss this year, leaving the ...

Among participants who met the core RESTORE-ALS Trial criteria (e.g., baseline serum NfL > 33 pg/mL, TRICALS risk score range between –6.5 and –2.5, baseline slow vital capacity > 60%, and symptom ...

Nevertheless, the new disappointment with DNL343 is another major disappointment to ALS patients, who have limited drug ...

Noon, is tackling ALS and other neurological disorders with a bold, multi-targeted approach. Fueled by a personal encounter ...

ALS, which is also known as Lou Gehrig's Disease, is a rare neurological disease that affects motor neurons — the nerve cells ...

Positron emission tomography (PET) is a nuclear imaging technique used to diagnose conditions such as cancer. An innovative ...

Tetramethylpyrazine nitrone was safe for people with amyotrophic lateral sclerosis (ALS), but neither a high nor low daily ...

Pathmaker's MyoRegulator is designed to ease hyperexcitability and delivers an electrical current to the spinal cord and ...

With the successful results of PrimeC, the drug has opened more opportunities for treatment and long-term results in the health of people diagnosed with ALS. "These exciting long-term results ...

Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.

Scientists have long been racking their brains for ways to treat Alzheimer’s disease, the most common type of dementia.